Article Text
Abstract
Introduction Acute acoustic trauma (AAT) is a sensorineural hearing impairment due to exposure to an intense impulse noise which causes cochlear hypoxia. Hyperbaric oxygen therapy (HBO) could provide an adequate oxygen supply. The aim was to investigate the effectiveness of early treatment with combined HBO and corticosteroid therapy in patients with AAT compared with corticosteroid monotherapy.
Methods A retrospective study was performed on military personnel diagnosed with AAT between November 2012 and December 2017. Inclusion criteria for HBO therapy were hearing loss of 30 dB or greater on at least one, 25 dB or more on at least two, or 20 dB or more on three or more frequencies as compared with the contralateral ear.
Results Absolute hearing improvements showed significant differences (independent t-test) between patients receiving HBO and the control group at 500 Hz (p=0.014), 3000 Hz (p=0.023), 4000 Hz (p=0.001) and 6000 Hz (p=0.01) and at the mean of all frequencies (p=0.002). Relative hearing improvements were significantly different (independent t-test) at 4000 Hz (p=0.046) and 6000 Hz (p=0.013) and at all frequencies combined (p=0.005). Furthermore, the percentage of patients with recovery to the functional level required by the Dutch Armed Forces (clinical outcome score) was higher in the HBO group.
Conclusions Early-stage combination therapy for patients with AAT was associated with better audiometric results at higher frequencies and better clinical outcome score.
- hearing loss
- noise-induced
- hyperbaric oxygenation
Statistics from Altmetric.com
Footnotes
Contributors ABB: data inclusion and analysis, manuscript writing. ELvdV: patient inclusion, manuscript writing. P-JAMvO: patient inclusion, technical support and manuscript writing. FSB-H: patient inclusion and manuscript review. DAAK: manuscript review. IS: methodology and manuscript review. JAdR: patient and data inclusion, manuscript writing.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Not required.
Ethics approval Institutional Review Board approval was obtained from the local medical ethical review board (reference number W17_352 #17.410).
Provenance and peer review Not commissioned; internally peer reviewed.